Stay updated with breaking news from Two Randomized Phase. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Long-term intermittent use of ruxolitinib cream is well tolerated and provides disease control in adolescent patients with atopic dermatitis (AD), according to a study published online May 2 in the American Journal of Clinical Dermatology.
Incyte (NASDAQ:INCY) today announced multiple abstracts featuring new data from across its dermatology portfolio have been accepted for presentation at the upcoming European Academy of Dermatology and Venereology (EADV)
Incyte today announced multiple abstracts featuring new data from across its dermatology portfolio have been accepted for presentation at the upcoming European Academy of Dermatology and Venereology...
From a novel acne cream to a breakthrough depression drug, a half-dozen agent decisions are coming through in the coming 6 months.
Curious about PT-141 peptide therapy? Inside, we detail everything you need to know about the research chemical – dosing, benefits, side effects, and more.